Related resources and publications
VISTA - safety and PK profiling
Acta Biomater
Int J Pharmac
This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.
Our double-humanized serum albumin/neonatal Fc receptor mouse model (HSA/hFcRn) maintains an autologous receptor-ligand interaction and can mimic the physiological drug clearance in humans.
This upgraded, immunocompromised Rag1-/- system (HSA/hFcRn-Rag1-/-) allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.
Hemocytometer (A) and flow cytometry count of B and T cells in the thymus (B) and spleen (C) of wild-type (WT) and HSA/hFcRn/Rag1-/- (tHO) mice.
C57BL6 Rag1-/- (C57BL6 Rag1 KO) and HSA/hFcRn/Rag1-/- (AlbuMus RAG1 KO) mice were subcutaneously inoculated with HT-29 cells (colorectal cancer cells).
Original figure from Mandrup et al., Comm Biol 2021
HSA/hFcRn/Rag1-/- mice were subcutaneously inoculated with MDA-MB-231 (left) or MIA PaCa-2 (right) cells. Mice were randomized and treated either with vehicle or with an albumin-bound drug once a week for 4 weeks, when individual tumor reached 250mm3.
VISTA - safety and PK profiling
Acta Biomater
Int J Pharmac
Let us know how we can help